8 Considerations in the Differential Diagnosis of Posttraumatic Psychosis

Slideshow

Following TBI, cognitive deficits, comorbid medical and neurological problems, as well as complex pharmacotherapeutic needs and sensitivities frequently complicate evaluation and treatment of psychosis in this population.

Related Videos
Related Content

Antipsychotic Medication for Parkinson Disease Psychosis Receives Packaging Label Updates

September 19th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: September 11-15

September 16th 2023

What Will the Future of Alzheimer Disease Treatment Look Like?

July 23rd 2021

Special Populations Research Roundup: September 15

September 15th 2023

EMPOWERing the Next Generation

September 13th 2023

Antipsychotic Medication for Parkinson Disease Psychosis Receives Packaging Label Updates

September 19th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: September 11-15

September 16th 2023

What Will the Future of Alzheimer Disease Treatment Look Like?

July 23rd 2021

Special Populations Research Roundup: September 15

September 15th 2023

EMPOWERing the Next Generation

September 13th 2023

Antipsychotic Medication for Parkinson Disease Psychosis Receives Packaging Label Updates

September 19th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

The Week in Review: September 11-15

September 16th 2023

What Will the Future of Alzheimer Disease Treatment Look Like?

July 23rd 2021

Special Populations Research Roundup: September 15

September 15th 2023

EMPOWERing the Next Generation

September 13th 2023
© 2023 MJH Life Sciences

All rights reserved.